



**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17686 (OCU)	SERIAL NO.: 10/826,441
APPLICANT: Patrick M. Hughes et al.	TITLE: STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANT
FILING DATE: April 15, 2004	GROUP: 1645

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
KM	AA	2004/0033241 A1	19-FEB-04	DONOVAN	424	239.1	23-MAY-03
KM	AB	2003/0118598 A1	26-JUN-03	HUNT	424	184.1	05-NOV-02
KM	AC	2002/0098237 A1	25-JUL-02	DONOVAN et al.	424	484	11-MAR-02
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
KM	BA	WO 01/58472 A	05-FEB-01	PCT	A61K	38/16	Y
	BB						
	BC						
	BD						


**OTHER ART**

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	
	CB	
	CC	
	CD	
	CE	
	CF	
	CG	
	CH	

EXAMINER /Kerima Maasho/ DATE CONSIDERED 01/08/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17686 (OCU)	SERIAL NO.: 10/826,441
APPLICANT: Patrick M. Hughes et al.	TITLE: STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANT
FILING DATE: April 15, 2004	GROUP: 1645

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
KM	AA	4,853,224	08/01/1989	WONG	424	427	
KM	AB	4,997,652	03/05/1991	WONG	424	428	
KM	AC	5,164,188	11/17/1992	WONG	424	428	
KM	AD	5,378,475	01/03/1995	SMITH et al.	424	473	
KM	AE	5,443,505	08/22/1995	WONG et al.	623	4	
KM	AF	6,217,895	04/17/2001	GUO et al.	424	427	
KM	AG	6,548,078	04/15/2003	GUO et al.	424	423	
	AH						
	AI						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
	BB						
	BC						
	BD						

**OTHER ART**

(Including Author, Title, Date, Pertinent Pages, etc.)

KM	CA	Cheng, Cheng-Kuo et al., <i>Intravitreal Sustained-Release Dexamethasone Device in the Treatment of Experimental Uveitis</i> , Investigative Ophthalmology & Visual Science, February 1995, Vol. 36, No. 2, pp. 442-453
KM	CB	Enyedi, Laura B. et al., <i>An intravitreal device providing sustained release of cyclosporine and dexamethasone</i> , Current Eye Research, October 17, 1995, pp. 549-557
KM	CC	Hainsworth, Dean P. et al., <i>Sustained Release Intravitreal Dexamethasone</i> , Journal of Ocular Pharmacology and Therapeutics, Volume 12, Number 1, 1996, pp. 57-63
KM	CD	Kochinke, F. et al., <i>Biodegradable Drug Delivery System for Uveitis Treatment</i> , Investigative Ophthalmology & Visual Science, February 15, 1996, Vol. 37, No. 3, 186-B98
	CE	
	CF	
	CG	
	CH	

EXAMINER /Kerima Maasho/

DATE CONSIDERED 01/08/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**LIST OF ART CITED BY APPLICANT**

<b>ATTY. DOCKET:</b> 17686 (OCU)	<b>SERIAL NO.:</b> 10/826,441
<b>APPLICANT:</b> Patrick M. Hughes et al.	<b>TITLE:</b> STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANT
<b>FILING DATE:</b> April 15, 2004	<b>GROUP:</b>

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
KM	AA	3,523,906	08/01/1970	Masterman et al	424	427	
KM	AB	3,691,090	09/12/1972	Kitajima et al.	252	316	
KM	AC	3,737,337	06/05/1973	Schnoring et al	427	212	
KM	AD	4,389,330	06/21/1983	Tice et al.	427	213.36	
KM	AE	5,019,400	05/28/1991	Gamboty et al.	424	497	
KM	AF	5,989,545	11/23/1999	Foster et al.	424	183.1	
KM	AG	6,281,015	08/28/2001	Mooney et al.	435	395	
KM	AH	6,506,399	01/14/2003	Donovan	424	423	
	AI						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
	BB						
	BC						
	BD						

**OTHER ART**

(Including Author, Title, Date, Pertinent Pages, etc.)

KM	CA	Aoki, K., <i>Preclinical update on BOTOX® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations</i> , Eur J Neurol 1999 Nov; 6(Suppl 4):S3-S10
KM	CB	Bigalke H., et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> , Brain Research 360; 318-324:1985
KM	CC	Bigalke H., et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord</i> , Naunyn-Schmiedeberg's Arch Pharmacol 316; 244-251:1981

EXAMINER /Kerima Maasho/ DATE CONSIDERED 01/08/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF ART CITED BY APPLICANT**

<b>ATTY. DOCKET:</b> 17686 (OCU)	<b>SERIAL NO.:</b> 10/826,441
<b>APPLICANT:</b> Patrick M. Hughes et al.	<b>TITLE:</b> STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANT
<b>FILING DATE:</b> April 15, 2004	<b>GROUP:</b>

KM	CD	Coffield, J. et al., <i>The Site and Mechanism of Action of Botulinum Neurotoxin, Therapy With Botulinum Toxin</i> , Ed. Jankovic J. et al., Marcel Dekker, Inc., (1994), page 5
KM	CE	Gonelle-Gispert, C. et al., <i>SNAP-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion</i> , Biochem J. (1999) 339:159-65
KM	CF	Habermann E., et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain</i> , J Neurochem 51 (2);522-527:1988
KM	CG	Habermann E., <i>Inhibition by Tetanus and Botulinum A Toxin of the Release of [<sup>3</sup>H]Noradrenaline and [<sup>3</sup>H]GABA From Rat Brain Homogenate</i> , Experientia 44 (1988); 224-226
KM	CH	Habermann E., <i>I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord</i> , Naunyn-Schmiedeberg's Arch. Pharmacol. (1974) 281; 47-56
KM	CI	<i>Harrison's Principles of Internal Medicine</i> , edited by Anthony Fauci et al., 14.sup.th edition, published by McGraw Hill (1998)
KM	CJ	Marchese Ragona, R. et al., <i>Management of Parotid Sialoceles With Botulinum Toxin</i> , The Laryngoscope 109 (August 1999);1344-1346
KM	CK	<i>Movement Disorders</i> (1995), 10(3); 376
KM	CL	Naumann, M. et al., <i>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions</i> , European J. Neurology (1999) 6 (Supp 4): S111-S115
KM	CM	Neimann et al., <i>Clostridial neurotoxins: new tools for dissecting exocytosis</i> , Trends in Cell Biol. 4 (May 1994);179-185
KM	CN	Pearce, L. B., <i>Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine</i> , Toxicon (1997) 35(9); 1373-1412 at 1393
KM	CO	Sanchez-Prieto, J., et al., <i>Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes</i> , Eur J. Biochem (1987) 165;675-681
KM	CP	Schantz, E. J. et al, <i>Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine</i> , Microbiol Rev. (1992) 56; 80-99
KM	CQ	Singh, B., <i>Critical Aspects of Bacterial Protein Toxins</i> , pages 63-84 (chapter 4) of Natural Toxins II, edited by B. R. Singh et al., Plenum Press, New York (1996)

EXAMINER /Kerima Maasho/ DATE CONSIDERED 01/08/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF ART CITED BY APPLICANT**


ATTY. DOCKET: 17686 (OCU)	SERIAL NO.: 10/826,441
APPLICANT: Patrick M. Hughes et al.	TITLE: STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANT
FILING DATE: April 15, 2004	GROUP:

KM	CR	Sloop, R. et al., <i>Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use</i> , Neurology 48 (January 1997);249-53
KM	CS	Wiegand et al., <i>I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection</i> , Naunyn-Schmiedeberg's Arch. Pharmacol. 292 (1976); 161-165

EXAMINER /Kerima Maasho/ DATE CONSIDERED 01/08/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/826,441



Sheet 1 of 3

### LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17707 (OCU)	SERIAL NO.: 10/826,441
APPLICANT: PATRICK M. HUGHES et al.	TITLE: SUSTAINED RELEASE INTRAOCULAR IMPLANTS CONTAINING TYROSINE KINASE INHIBITORS AND RELATED METHODS
FILING DATE: April 30, 2004	GROUP: 1615

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,378,475	01/03/1995	SMITH et al.	424	473	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
	BB						
	BC						
	BD						

### OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Enyedi, Laura B. et al., <i>An intravitreal device providing sustained release of cyclosporine and dexamethasone</i> , Current Eye Research, October 17, 1995, pp. 549-557
	CB	Hainsworth, Dean P. et al., <i>Sustained Release Intravitreal Dexamethasone</i> , Journal of Ocular Pharmacology and Therapeutics, Volume 12, Number 1, 1996, pp. 57-63
	CC	
	CD	
	CE	
	CF	
	CG	
	CH	

EXAMINER

*Kevin K. Maash*

DATE CONSIDERED

*01/08/2007*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.